phone icon  Int'l : +1 (503) 505-6949
0
Shopping Cart is Empty..
$ 0

World Lung Cancer Therapeutics Market - Opportunities and Forecasts, 2014 -2020

 Report Code: PH 15351
 Pages: 0
 Format: PDF Exel CD_rom
 Upcoming Date: Oct 2015
tab_nTables: 0
aut_nAuthor(s):

Lung cancer is a malignant lung carcinoma that is characterized by abnormal cell growth in lung tissue. As the tumor grows in size, it decreases the lungs’ ability to provide oxygen to bloodstream. The primary lung carcinomas originate from epithelial cells and classified as non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Major symptoms of lung cancer include coughing, body mucus, wheezing, shortness of breath, chest pain and weight loss. Lung cancer has high mortality rate all over the globe and the foremost reason includes cigarette smoking. Treatments of lung cancer include chemotherapy and radiation therapy. This report provides in-depth discussion on global lung cancer therapeutics market and includes past and current trends with future forecast up to 2020. The report provides threats and opportunities for new and existing companies running the business in this market. The report is informative towards geographical segmentation and identifies profitable areas.

Global lung cancer therapeutics market shows promising CAGR due to increasing population of lung cancer and it is expected that trend would continue with the same momentum. Advanced stages of lung cancer still show high unmet need for diagnosis and treatment. The potential drivers for lung cancer therapeutic market include tobacco smoking (including passive smoke), aged population and lifestyle factors. Additionally, innovative and targeted drug delivery to lung is found to be a major driver for the growth of this market. However, high unmet need for diagnosis, availability of large number of generic forms of major drugs and limited treatment options are the critical restrains to the global lung cancer therapeutics market. Chemotherapy and radiation therapy poses bigger challenge of adverse effect. Hence, big players in this market have to focus on innovative therapies and safer therapeutics. 

Global Lung Cancer Therapeutics Market by TherapeuticsThe global lung cancer therapeutics market is segmented by therapy into five broad categories, namely Chemotherapy, Targeted therapy and Pipeline drugs, Surgery and Radiotherapy. NSCLC contributes for high prevalence than SCLC. Avastin by Roche was the blockbuster drug for the past few years that accounted for major percentage of the total sale. Other top brands of therapeutics include Gemzar, Taxotere and Tarceva and used for NSCLC. For SCLC treatment, ifosfamide or etoposide is combined with platinum analog and forms standard chemotherapeutic regimen. Many a times, Radiotherapy in combination with chemotherapy, is used as better option before surgery to increase the effectiveness of the treatment. Key Challenge in successful pipeline therapy includes its integration with existing therapy or its superiority over existing therapy.

Global Lung Cancer Therapeutics Market by GeographyGeographically, global lung cancer therapeutics market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America and Europe are the leading global lung cancer therapeutic markets due to high incidences and large pool of aging population. Additionally, lifestyle standard with high smoking habits leads to a large pool of lung carcinoma population. Asia-Pacific is the emerging market, where India has shown high incidence in past few years, whereas, LAMEA contributes to smaller volume as compared to North America and Europe.

Competitive LandscapeThe leading companies in global lung cancer therapeutics market include Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Pfizer, and Agennix AG. Currently, Roche, Agennix AG and Pfizer are ruling the market for global lung cancer therapeutics and expected to capture half of the market share during the forecast period. Decline in sales value of AstraZeneca was attributed to large number of generic drugs entering the market. Eli Lilly has achieved a top position next to AstraZeneca and Sanofi-Aventis due to exceptional sales performance of its key product Alimta.  

High Level AnalysisThe study identifies the potential market drivers, challenges and trends. Competitive landscape section provides explicit information of the big players ruling the global lung cancer therapeutics market, their operating strategies, new launches, pipeline therapies and clinical trials. Porter’s five forces analysis has been used to determine the attractiveness of global lung cancer therapeutics market. Chemotherapy and radiation therapy shows large number of side effects and many a times need to be followed by surgery. Hence, constant demand for safe and efficacious therapeutics and improved technology is responsible to increase the bargaining power of suppliers. Large number of generic drugs is entering the market and therefore, the threat of substitute products tends to be high. To fulfill the demand for safe and effective drug therapy, many companies are putting their effort to pipeline research. Thus, it led to commercialization of large number of products and due to which rivalry is intense among participants.

KEY BENEFITS

  • This report offers the following benefits in particular:
  • Comprehensive coverage of global lung cancer therapeutics market along with disease overview, market trends, drivers and restraints
  • Through attention is given to leading company portfolios, pipeline research, new launches and competitive landscape of top players
  • Explicit information on current clinical trials and R&D activities, would be beneficial to understand the future market trends  
  • Insightful analysis of different segments helps to recognize and capitalize future opportunities within global lung cancer therapeutics market

KEY DELIVERABLESThe global lung cancer therapeutics market is segmented into two major categories such as, therapeutics and geography. MARKET BY THERAPY

  • Chemotherapy
    • Taxotere
    • Hycamtin
    • Navelbine
    • Gemzar
    • Alimta
  • Targeted therapy
    • Tarceva
    • Iressa
    • Avastin
  • Pipeline drugs
    • Talactoferrin 
    • Dacomitinib
    • Afatinib
    • Erbitux
    • ARQ 197
    • Ramucirumab
  • Surgery
    • Pneumectomy (Removal of whole lung)
    • Bilobectomy (Removal both lobes)
    • Lobectomy (removal of one lobe)
  • Radiotherapy

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
Let us know more about your research need and we will customize an offer exclusively for you!
*
*
*
*
*
*
*
security
*

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
SINGLE USER
GROUP LICENSE
SITE LICENSE
GLOBAL LICENSE
$3951
$4527
$5880
$8010
SUPPORT
Delivery Formats
20% Free customization (Pre-sale)
16 Analyst hour support (Post Sale)
40 Analyst hour support (Post Sale)
160 hours of mini-consult
Free quarterly industry update
Free report on update (within 180 days)
MULTIPLE PURCHASE
Complimentary report with 2 reports
Complimentary report with 3 reports
Subscription Model
Have questions ?
connect
Need to add more ?
request

Get This Report
buy now
First time buyer ?
Check offers and discount
on this report
REQUEST QUOTE
Need More Information
phone_n +1 (503) 505-6949

Help AMR help@alliedmarketresearch.com
Or
Send Enquiry
WHY ALLIED MARKET RESEARCH?
Infallible Methodology
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader
RECENTLY VIEWED REPORTS
get_n
SIMILAR MARKET REPORTS
  • ...
    Rise in incidence of diabetes across the globe has elevated the need of innovative diabetic management devices that has increased adoption of continuous glucose monitoring (CGM) devices. The existing glucose monitoring devices have few gaps which are bridged by the innovative CGM. With continuous glucose monitoring, significant improvement has been observed in stabilizing elevated A1C levels which in turn reduces risk of developing long term diabetic complications. Other driving factors for CGM market are technological innovation in the form of artificial pancreas, increasing awareness among developed, developing and under developed economies, and rise in incidences of diabetic cases.
    Dec 2013 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications.
    Jul 2015 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Synthetic biology is a novel field that finds its origin at the intersection of biology and engineering. It involves designing and construction of biological systems or devices that can be applied in varied domains to get specified results. Its a multidisciplinary effort made by scientists to understand the functioning of biological organisms, cells & genes and implementation of artificial genetic processes to give specific characteristics to an organism. It can even be used to develop a completely new biological system. Global synthetic biology market was valued at $3.0 billion in 2013 and it is estimated to reach $38.7 billion by 2020, growing at a CAGR of 44.2% during the forecast period.
    May 2014 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Medical nonwoven disposables are indispensable products in the field of healthcare. These products are surpassing woven fabrics in terms of popularity as they offer better hygiene conditions and effectively aid in avoiding contamination and infections. Rise in the incidences of Hospital-acquired infections and incontinence problems in adults globally are creating a need for medical nonwoven disposables in the market.
    Jun 2015 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
ON DEMAND REPORTS
  • ...
    Heart block is the disease of cardiovascular electrical system, which controls the rhythm and rate of the heart. Heart block mainly occurs due to disturbed and slowed electrical signals across the heart. Heart block is categorized in two types on the basis of working of the cardiovascular electric signals; partial heart blocks and complete heart blocks. In the partial heart blocks, the cardiovascular electrical signals are partially blocked i.e., their influx to heart is delayed.
    Oct 2015 | View Details >>
  • ...
    Antihypertensives are the drugs that are used to treat high blood pressure. Increase in blood pressure is measured in terms of systolic and diastolic blood pressure exerted by blood on the wall of artery and hence it is also termed as arterial hypertension. Antihypertensive drugs alleviate the complications of stroke and myocardial infarction. Reduction in blood pressure minimizes the risk of heart failure, ischaemic heart diseases, dementia and mortality due to hypertension. Changes in lifestyle are the prime factors that increase the number hypertensive cases.
    Oct 2015 | View Details >>
  • ...
    Increased investments, governments providing funds and grants, rising collaborations and research-related activities, technological innovations, widening of biomaterial applications in medical device market, and rise in ageing population are the major factors that are expected to drive the market globally. Additionally, the global medical devices market is projected to reach over $230.0 billion by 2020, with a CAGR of 6.8% from 2013 to 2020, which will also propel the growth of biomaterials with respect to the medical devices market.
    Oct 2015 | View Details >>
  • ...
    Rise in the population of people aged 65 and above, increasing cardiovascular diseases, trauma related with old age, increase in congenital disorders and increasing demand of faster and efficient health solutions are expected to drive the global medical implant market. However there are certain factors that restrain the growth of market such as high cost of implants, unavailability of need expertise and uncertain reimbursement scenarios in various regions.
    Oct 2015 | View Details >>